Charles Zhu
Stock Analyst at LifeSci Capital
(4.84)
# 419
Out of 4,355 analysts
266
Total ratings
62.2%
Success rate
25.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintained: Buy | $28 | $10.20 | +174.51% | 29 | May 26, 2026 | |
| STRO Sutro Biopharma | Maintained: Buy | $54 | $29.23 | +84.74% | 3 | May 26, 2026 | |
| NUVL Nuvalent | Maintained: Buy | $142 | $110.39 | +28.63% | 24 | May 26, 2026 | |
| TARA Protara Therapeutics | Maintained: Buy | $26 | $4.65 | +459.14% | 19 | May 20, 2026 | |
| IMNM Immunome | Maintained: Buy | $40 | $21.83 | +83.23% | 15 | May 16, 2026 | |
| MOLN Molecular Partners AG | Maintained: Buy | $12 | $4.20 | +185.72% | 16 | May 16, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $6 | $2.85 | +110.53% | 6 | May 15, 2026 | |
| ZYME Zymeworks | Rated: Buy | $34 | $25.13 | +35.30% | 26 | May 9, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $62 | $29.47 | +110.38% | 48 | May 9, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $263 | $157.48 | +67.01% | 21 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $2.38 | +152.10% | 12 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.97 | +101.51% | 8 | May 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $28 | $20.65 | +35.59% | 10 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $22 | $5.91 | +272.25% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $21.98 | n/a | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $20 | $4.16 | n/a | 6 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $34.96 | n/a | 4 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 → $39 | $11.88 | n/a | 4 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.46 | n/a | 3 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $28.34 | n/a | 3 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $20 | $1.20 | n/a | 4 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $2.00 | $0.425 | n/a | 1 | Nov 29, 2022 |
Kura Oncology
May 26, 2026
Maintained: Buy
Price Target: $28
Current: $10.20
Upside: +174.51%
Sutro Biopharma
May 26, 2026
Maintained: Buy
Price Target: $54
Current: $29.23
Upside: +84.74%
Nuvalent
May 26, 2026
Maintained: Buy
Price Target: $142
Current: $110.39
Upside: +28.63%
Protara Therapeutics
May 20, 2026
Maintained: Buy
Price Target: $26
Current: $4.65
Upside: +459.14%
Immunome
May 16, 2026
Maintained: Buy
Price Target: $40
Current: $21.83
Upside: +83.23%
Molecular Partners AG
May 16, 2026
Maintained: Buy
Price Target: $12
Current: $4.20
Upside: +185.72%
Context Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $6
Current: $2.85
Upside: +110.53%
Zymeworks
May 9, 2026
Rated: Buy
Price Target: $34
Current: $25.13
Upside: +35.30%
IDEAYA Biosciences
May 9, 2026
Maintained: Buy
Price Target: $62
Current: $29.47
Upside: +110.38%
Revolution Medicines
May 9, 2026
Maintained: Buy
Price Target: $263
Current: $157.48
Upside: +67.01%
May 9, 2026
Maintained: Buy
Price Target: $6
Current: $2.38
Upside: +152.10%
May 2, 2026
Reiterated: Buy
Price Target: $8
Current: $3.97
Upside: +101.51%
Apr 30, 2026
Maintained: Buy
Price Target: $22 → $28
Current: $20.65
Upside: +35.59%
Jun 18, 2025
Initiated Coverage: Buy
Price Target: $22
Current: $5.91
Upside: +272.25%
May 24, 2024
Maintained: Buy
Price Target: $14
Current: $21.98
Upside: n/a
Jan 2, 2024
Maintained: Buy
Price Target: $12 → $20
Current: $4.16
Upside: n/a
Jun 13, 2023
Reiterated: Buy
Price Target: $26
Current: $34.96
Upside: n/a
May 9, 2023
Maintained: Buy
Price Target: $45 → $39
Current: $11.88
Upside: n/a
Mar 17, 2023
Maintained: Buy
Price Target: $5
Current: $1.46
Upside: n/a
Jan 3, 2023
Maintained: Hold
Price Target: n/a
Current: $28.34
Upside: n/a
Jan 3, 2023
Maintained: Buy
Price Target: $30 → $20
Current: $1.20
Upside: n/a
Nov 29, 2022
Initiated Coverage: Buy
Price Target: $2.00
Current: $0.425
Upside: n/a